Advertisement


Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

2025 ASCO Annual Meeting

Advertisement

Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
On behalf of the ARASENS investigators, I was very pleased to present the ARASENS quality of life data. ARASENS is a phase three study in patients with metastatic hormone-sensitive prostate cancer. Patients were enrolled and were randomized to ADT plus darolutamide versus ADT and placebo to assess a primary endpoint of radiographic progression-free survival of darolutamide in this setting. Importantly, patients who were enrolled were predominantly high-volume metastatic disease and most had de novo metastatic hormone-sensitive disease. In terms of the quality of life analysis, patients were assessed by the Brief Pain. In the patients treated with ADT plus darolutamide versus ADT alone. I think also importantly the subscales of the FACT-P that were analyzed did suggest that certain subscales were improved more than others including urinary symptoms and prostate cancer-specific symptoms as well as functional well-being and social well-being, suggesting that patients were reporting that they had better time with their families and performing their daily activities. Ultimately, these suggest that darolutamide in the addition to ADT were improving metastatic hormone-sensitive prostate cancer patients' quality of life in addition to being associated with the radiographic progression-free survival advantage for this combination.

Related Videos

Breast Cancer

Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with ER-positive HER2-negative advanced breast cancer. Vepdegestrant is the first PROTAC to be evaluated in a phase III trial (Abstract LBA1000). 

Prostate Cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

Breast Cancer
Issues in Oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508). 

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). 

 

Genomics/Genetics

Arelis Esther Martir-Negron, MD, on Prevalence of BRCA Variants in Hispanic Residents of South Florida

South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579). 

Advertisement

Advertisement




Advertisement